| Literature DB >> 24736683 |
Taisiya A Parkhomenko1, Vasilii B Doronin2, Massimiliano Castellazzi3, Marina Padroni3, Michela Pastore3, Valentina N Buneva4, Enrico Granieri3, Georgy A Nevinsky4.
Abstract
It was found that high-affinity anti-DNA antibodies were one of the major components of the intrathecal IgG response in multiple sclerosis (MS) patients [Williamson et al., PNAS, 2001]. Recently we have shown that IgGs from the sera of MS patients are active in the hydrolysis of DNA. Here we have shown, for the first time, that average concentration of total proteins (132-fold), total IgGs (194-fold) and anti-DNA antibodies (200-fold) in the sera is significantly higher than that in the cerebrospinal fluid (CSF) of fifteen MS patients. The relative activities of total protein from sera and CSFs varied remarkably from patient to patient. It was surprising that the specific DNase activity of the total protein of CSF reparations were 198-fold higher than the serum ones. Electrophoretically and immunologically homogeneous IgGs were obtained by sequential affinity chromatography of the CSF proteins on protein G-Sepharose and FPLC gel filtration. We present first evidence showing that IgGs from CSF not only bind but efficiently hydrolyze DNA and that average specific DNase activity of homogeneous antibodies from CSF is unpredictably ∼49-fold higher than that from the sera of the same MS patients. Some possible reasons of these findings are discussed. We suggest that DNase IgGs of CSF may promote important neuropathologic mechanisms in this chronic inflammatory disorder and MS pathogenesis development.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24736683 PMCID: PMC3988009 DOI: 10.1371/journal.pone.0093001
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Several different characteristics of MS patients.
| Number of patient | Sex | Age, years | Clinical course | Clinical activity | MRI activity |
| 1 | male | 59 | PP | yes | yes |
| 2 | female | 28 | RR | no | no |
| 3 | female | 36 | RR | yes | yes |
| 4 | male | 26 | RR | yes | no |
| 5 | male | 49 | RR | no | no |
| 6 | female | 20 | RR | yes | no |
| 7 | female | 46 | PP | yes | no |
| 8 | female | 51 | RR | yes | yes |
| 9 | female | 31 | RR | yes | no |
| 10 | female | 26 | RR | no | no |
| 11 | female | 43 | RR | yes | yes |
| 12 | male | 45 | RR | yes | no |
| 13 | female | 30 | RR | no | yes |
| 14 | female | 60 | RR | yes | no |
| 15 | female | 34 | RR | yes | yes |
*Relapsing–remitting (RR) and primary progressive (PP) MS.
**Clinical activity = presence of relapse at the time of sampling.
MRI activity = presence or absence gadolinium enhancing lesions at MRI examination.
The relative concentration of total protein, IgGs, and anti-DNA antibodies in CSF and sera of patients with MS.*
| Num. of patient | Relative concentration of total proteins, mg/ml | Relative concentration of total IgGs, mg/ml | Relative concentration of total anti-DNA Abs, A450
| |||
| CSF (1) | Serum (2) | CSF (3) | Serum (4) | CSF (5) | Serum (6) | |
| 1 | 0.55 | 59 | 0.11 | 11.9 | 0.22 | 110 |
| 2 | 0.33 | 63 | 0.19 | 9.3 | 0.24 | 2000 |
| 3 | 0.26 | 72 | 0.03 | 12.8 | 0.21 | 300 |
| 4 | 0.51 | 63 | 0.06 | 11.6 | 0.21 | 160 |
| 5 | 0.64 | 48 | 0.06 | 10.6 | 0.22 | 110 |
| 6 | 0.58 | 64 | 0.05 | 11.4 | 0.22 | 290 |
| 7 | 0.56 | 64 | 0.11 | 10.8 | 0.22 | 430 |
| 8 | 0.66 | 74 | 0.14 | 14.5 | 0.23 | 320 |
| 9 | 0.37 | 73 | 0.08 | 16.6 | 0.21 | 210 |
| 10 | 0.39 | 60 | 0.03 | 10.1 | 0.23 | 370 |
| 11 | 0.42 | 58 | 0.02 | 14.9 | 0.21 | 130 |
| 12 | 0.53 | 77 | 0.05 | 10.0 | 0.24 | 260 |
| 13 | 0.39 | 57 | 0.03 | 10.0 | 0.23 | 850 |
| 14 | 0.47 | 58 | 0.09 | 12.6 | 0.22 | 790 |
| 15 | 0.48 | 47 | 0.02 | 7.9 | 0.22 | 220 |
| Average values | 0.48±0.09 | 62.5±6.7 | 0.07±0.04 | 11.7±1.8 | 0.22±0.008 | 437±311 |
| Ratio of the values | 130 | 167 | 1986 | |||
| Coefficient correlation | −0.12 (p<0.05) | +0.074 (p<0.05) | +0.57 (p<0.05) | |||
| Coefficients of correlation between different values corresponding to numbers of this Table columns | ||||||
| Numbers | 1 and 3 | 1 and 5 | 2 and 4 | 2 and 6 | 3 and 5 | 4 and 6 |
| Coefficient correlation | +0.17 (p<0.05) | +0.11 (p<0.05) | +0.47 (p<0.05) | −0.004 (p<0.05) | +0.4 (p<0.05) | +0.32 (p<0.05) |
*For each value, a mean of three measurements is reported; the error of the determination of values did not exceed 7–10%.
**Average values are reported as mean ± S.E.
Different dilution CSF (2-fold) and serum (1000-fold) preparations were used; relative content was recalculated for initial undiluted CSFs and sera.
Figure 1SDS-PAGE analysis of total proteins corresponding to the sera (40 µg) (A) and CSFs (30 µg) (B) of several MS patient in a nonreducing 3–16% gradient gel followed by Coomassie staining.
The arrows (lane C) indicate the positions of molecular mass markers. The relative DNase activity of total protein preparations corresponding to the serum (C) and CSF (D) of several patients. Reaction mixtures were incubated for 2 h at 37°C and contain initial protein preparations diluted finally 1000- and 15-fold in the case of serum and CSF preparations, respectively; Lanes C (C and D) correspond and scDNA incubated without Abs.
Relative DNase activity of total proteins and IgGs from CSF and sera of patients with MS.*.
| Number of patient | Relative specific DNase activity of total proteins; pmole DNA/1 mg of protein/1 h | Relative DNase activity of total proteins; pmole DNA/1 ml of initial solution/1 h | Relative specific DNase activity of IgGs; pmole DNA/1 mg of Ab/1 h | ||||||
| CSF (7) | Serum (8) | CSF (9) | Serum (10) | CSF (11) | Serum (12) | ||||
| 1 | 118 | 0.41 | 64 | 24 | 528.9 | 17.5 | |||
| 2 | 70 | 0.38 | 23 | 24 | 716 | 5.2 | |||
| 3 | 263 | 0.33 | 69 | 23 | 778.9 | 3.6 | |||
| 4 | 118 | 0.43 | 62 | 27 | nd | nd | |||
| 5 | 25 | 0.72 | 16 | 34 | 564.6 | 10.5 | |||
| 6 | 62 | 0.26 | 36 | 17 | nd | nd | |||
| 7 | 55 | 0.43 | 31 | 28 | 544.2 | 13.1 | |||
| 8 | 25 | 0.46 | 14 | 34 | 129.3 | 17.6 | |||
| 9 | 78 | 0.47 | 29 | 34 | 117.3 | 17,0 | |||
| 10 | 44 | 0.75 | 17 | 45 | 210.9 | 7.8 | |||
| 11 | 133 | 0.61 | 56 | 35 | 1190.5 | 20.8 | |||
| 12 | 100 | 0.33 | 53 | 25 | 928.6 | 12.2 | |||
| 13 | 244 | 0.76 | 95 | 44 | 171.8 | 3.9 | |||
| 14 | 78 | 0.88 | 51 | 51 | 629.3 | 11.6 | |||
| 15 | 100 | 0.43 | 44 | 20 | 552.7 | 10.4 | |||
| Average value | 101±50 | 0.51±0.16 | 41.3±18.8 | 31±8 | 543.3±239.7 | 11.2±4.3 | |||
| Ratio of the values | 198.0 | 1.3 | 48.5 | ||||||
| Coefficient correlation | −0.05 (p<0.05) | 0.03 (p<0.05) | 0.26 (p<0.05) | ||||||
| Coefficients of correlation between different values corresponding to column numbers of | |||||||||
| Numbers | 1 and 7 | 2 and 8 | 3 and 11 | 4 and 12 | 5 and 11 | 6 and 2 | |||
| Coefficient correlation | +0.61 (p<0.05) | −0.49 (p<0.05) | +0.16 (p<0.05) | +0.58 (p<0.05) | +0.11 (p<0.05) | +0.51 (p<0.05) | |||
*For each value, a mean of three measurements is reported; the error of the determination of values did not exceed 7–10%.
**Average values are reported as mean ± S.E.
No determined.
Figure 2SDS-PAGE analysis of IgGmix (7 µg) corresponding to 13 CSFs of MS patients in 3–16% gradient gel before (lane 2) and after treatment with DTT (lane 3) followed by silver staining (A).
The arrows (lane 1) indicate the positions of molecular mass markers. In-gel assay of DNase activity of IgGmix (15 µg) in a gel containing DNA before (lane 3) and after treatment with DTT (lane 4, B). DNase activity was revealed by ethidium bromide staining as a dark band on the fluorescent background. A part of the gel corresponding to lanes 3 and 4 was stained with Coomassie R250 to show the position of intact IgGs (lane 1) and separated light and heavy chains (lane 2) (B). FPLC gel filtration of one IgGmix on a Superdex 200 column in an acidic buffer (pH 2.6) after Abs incubation in the same buffer (C) and its affinity chromatography on Sepharose bearing mouse IgGs against human IgGs (D): (–), absorbance at 280 nm (A280); (○), relative activity (RA) of IgGmix in the hydrolysis of scDNA. A complete hydrolysis of 20 µg/ml scDNA for 4 h was taken for 100%. The error in the initial rate determination from two experiments in each case did not exceed 7–10%. For details, see Materials and methods.
Figure 3DNase activity of individual IgGs from several CSFs (A) and sera (B) of MS patients in the cleavage of scDNA.
The reaction mixtures were incubated with the IgGs from CSFs (0.003 mg/ml) and sera (0.2 mg/ml) for 2 h at 37°C. Lane C in each group of IgGs corresponds to scDNA incubated without Abs mark the positions of supercoiled (scDNA) and relax DNA plasmid (relDNA) are shown.